Financials Sector Analysis

309 tickers in Financials
Ranks this page's recent reports by score.
Cullen/Frost Bankers, Inc.
CFR·Financials
B ★★★Hold
Current$157.60
Target$169.96
Return+7.8%
Nov 1, 2026

Cullen/Frost combines a durable Texas deposit franchise, strong capital, and consistent earnings growth, but its premium tangible-book valuation and sensitivity to funding costs limit the margin of safety.

Score
71
Virtu Financial, Inc.
VIRT·Financials
B ★★★Hold
Current$53.76
Target$65.00
Return+20.9%
Nov 1, 2026

Virtu Financial combines scalable electronic market-making technology, high capital returns, and attractive earnings multiples, but its long-term valuation depends on whether elevated trading profitability survives market normalization.

Score
73
Rocket Companies, Inc.
RKT·Financials
B ★★★Hold
Current$12.80
Target$14.20
Return+10.9%
Nov 1, 2026

Rocket's integrated mortgage and servicing ecosystem could deliver substantial earnings growth through recapture and efficiency gains, but mortgage cyclicality, acquisition leverage, and demanding normalized earnings expectations limit near-term upside.

Score
67
Aflac Incorporated
AFL·Financials
B ★★★Hold
Current$123.89
Target$121.92
Return-1.6%
Nov 1, 2026

Aflac offers durable supplemental insurance franchises, strong adjusted returns on equity, and disciplined shareholder distributions, but mature Japanese demand, U.S. claims pressure, and demanding valuation limit near-term upside.

Score
66
Blue Owl Capital Inc.
OWL·Financials
B ★★★Hold
Current$10.33
Target$12.48
Return+20.8%
Nov 1, 2026

Blue Owl's recurring private-market fees, growing AUM, and high dividend yield offer an attractive long-term income-and-growth opportunity, but private-credit risks, substantial equity compensation, and dilution threaten per-share returns.

Score
74
KKR & Co. Inc.
KKR·Financials
A ★★★★Buy
Current$94.39
Target$112.00
Return+18.7%
Nov 1, 2026

KKR offers long-term compounding through expanding alternative assets, high-margin recurring fees and insurance integration at an attractive forward valuation, although credit losses and weak investment exits could impair earnings.

Score
82
Banco Bilbao Vizcaya Argentaria, S.A.
BBVA·Financials
B ★★★Hold
Current$23.44
Target$26.40
Return+12.6%
Nov 1, 2026

BBVA combines exceptional banking profitability, strong Mexican growth and substantial capital returns, but its historically elevated book valuation and emerging-market credit exposure limit the margin of safety.

Score
72
Intercontinental Exchange, Inc.
ICE·Financials
S ★★★★★Strong Buy
Current$168.85
Target$193.20
Return+14.4%
Nov 1, 2026

ICE combines entrenched exchange network effects, recurring financial data revenue, and strong cash generation at an attractive valuation, although MarketAxess acquisition financing and integration introduce meaningful execution risk.

Score
86
ING Groep N.V.
ING·Financials
B ★★★Hold
Current$31.46
Target$34.10
Return+8.4%
Nov 1, 2026

ING combines a durable European deposit franchise, strong tangible-equity returns and substantial shareholder distributions, but its historical valuation premium and sensitivity to interest rates and credit losses limit the margin of safety.

Score
74
Tradeweb Markets Inc.
TW·Financials
A ★★★★Buy
Current$122.54
Target$133.90
Return+9.3%
Nov 1, 2026

Tradeweb combines a durable electronic fixed-income trading network, strong cash generation, and structural market growth, but premium valuation and the $1.97B Trumid acquisition create execution and downside risks.

Score
78
Houlihan Lokey, Inc.
HLI·Financials
A ★★★★Buy
Current$138.00
Target$163.59
Return+18.5%
Nov 1, 2026

Houlihan Lokey combines a durable independent advisory franchise, strong profitability, and M&A recovery potential at a reasonable valuation, although cyclical deal activity and compensation costs remain important earnings risks.

Score
77
AXIS Capital Holdings Limited
AXS·Financials
B ★★★Hold
Current$104.87
Target$121.80
Return+16.1%
Nov 1, 2026

AXIS Capital combines profitable specialty underwriting, strong operating ROE, and substantial buybacks, but catastrophe exposure and a historically elevated price-to-book multiple constrain its margin of safety.

Score
72